Crispr Therapeutics AG (NASDAQ:CRSP) – Oppenheimer issued their Q2 2020 earnings per share (EPS) estimates for Crispr Therapeutics in a research report issued on Tuesday, November 12th, according to Zacks Investment Research. Oppenheimer analyst S. Tuerkcan anticipates that the company will post earnings of ($0.95) per share for the quarter. Oppenheimer has a “Outperform” rating and a $80.00 price objective on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q3 2020 earnings at ($1.29) EPS and Q4 2020 earnings at ($1.38) EPS.

A number of other equities analysts also recently weighed in on the stock. Roth Capital lifted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a report on Tuesday, November 26th. Chardan Capital reissued a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research note on Monday, November 18th. Finally, Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $69.54.

Crispr Therapeutics stock traded up $1.66 during mid-day trading on Wednesday, hitting $72.37. 892,934 shares of the stock were exchanged, compared to its average volume of 703,877. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm’s fifty day simple moving average is $54.81 and its two-hundred day simple moving average is $47.38. The stock has a market capitalization of $4.00 billion, a price-to-earnings ratio of -21.04 and a beta of 3.30.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Benjamin Edwards Inc. boosted its position in shares of Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares during the last quarter. NEXT Financial Group Inc boosted its holdings in Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the last quarter. US Bancorp DE boosted its holdings in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the last quarter. Coastal Investment Advisors Inc. bought a new stake in shares of Crispr Therapeutics in the 3rd quarter worth $26,000. Finally, BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics in the 2nd quarter worth $39,000. Hedge funds and other institutional investors own 49.81% of the company’s stock.

In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock valued at $3,620,760. Insiders own 21.40% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: The role of implied volatility with call option volume

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link